William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on June 18.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors related to the anticipated CMS reimbursement announcement for PROCEPT BioRobotics. The transition of Aquablation into a Category 1 code is expected to provide clarity and potentially act as a positive catalyst for the stock. The current physician payment for Aquablation is comparable to or slightly above other key procedures, which is viewed positively despite potential declines in reimbursement rates across the board.
Additionally, the stability in the Ambulatory Payment Classification (APC) level, which reimburses hospitals over $9,000 per procedure, is expected to remain unchanged, contributing positively to hospital economics. This stability, along with the potential simplification of market access due to the Category 1 transition, supports the company’s growth outlook. With the stock trading at seven times the projected 2026 sales, the continued strong growth of the company underpins the Outperform rating ahead of the reimbursement announcements.
In another report released on June 18, Truist Financial also reiterated a Buy rating on the stock with a $70.00 price target.